SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+16.81%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$268M
AUM Growth
+$268M
(-9.4%)
Cap. Flow
+$4.07M
Cap. Flow
% of AUM
1.52%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
95
New
14
Increased
33
Reduced
15
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.76M |
| 3 |
UroGen Pharma
URGN
|
$7.13M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$6.54M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.41M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$10.6M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$10.2M |
| 3 |
Schrodinger
SDGR
|
$7.23M |
| 4 |
Krystal Biotech
KRYS
|
$5.5M |
| 5 |
89bio
ETNB
|
$5.19M |
Sector Composition
| 1 | Healthcare | 99.9% |
| 2 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $20.7M | 6.29% | 1,307,435 -112,565 | -8% | -$1.79M |
|
|
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $13.5M | 4.1% | 590,829 +338,520 | +134% | +$7.76M |
|
3
Merus
MRUS
$4.98B
| $11.8M | 3.57% | 500,000 -89,255 | -15% | -$2.1M |
|
|
4
Soleno Therapeutics
SLNO
$3.6B
| $10.9M | 3.31% | +370,000 | New | +$10.9M |
|
|
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.9M | 3.3% | 208,730 +10,007 | +5% | +$521K |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $8.8M | 2.67% | 590,000 +430,000 | +269% | +$6.41M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.71M | 2.64% | 200,000 +108,787 | +119% | +$4.74M |
|
|
PSTX
8
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $8.49M | 2.57% | 3,567,985 +622,037 | +21% | +$1.48M |
|
|
9
Krystal Biotech
KRYS
$4.27B
| $8.3M | 2.52% | 71,531 -47,410 | -40% | -$5.5M |
|
10
Biogen
BIIB
$19.4B
| $7.21M | 2.19% | 28,069 +1,215 | +5% | +$312K |
|
|
11
UroGen Pharma
URGN
$900M
| $7.13M | 2.16% | +508,883 | New | +$7.13M |
|
12
United Therapeutics
UTHR
$13.8B
| $7.1M | 2.15% | 31,424 +1,395 | +5% | +$315K |
|
13
Praxis Precision Medicines
PRAX
$958M
| $7.04M | 2.14% | 4,117,920 +641,758 | +18% | +$1.1M |
|
14
Oric Pharmaceuticals
ORIC
$994M
| $6.8M | 2.06% | 1,123,345 -327,477 | -23% | -$1.98M |
|
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.54M | 1.98% | +220,000 | New | +$6.54M |
|
16
Cogent Biosciences
COGT
$1.69B
| $6.35M | 1.93% | 651,372 +31,372 | +5% | +$306K |
|
17
Mersana Therapeutics
MRSN
$36.5M
| $6.35M | 1.93% | 5,000,000 +4,000,000 | +400% | +$5.08M |
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $5.97M | 1.81% | 260,537 +144,369 | +124% | +$3.31M |
|
19
MacroGenics
MGNX
$112M
| $5.89M | 1.79% | 1,264,158 +48,483 | +4% | +$226K |
|
20
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.61M | 1.7% | 791,671 +30,767 | +4% | +$218K |
|
21
Novo Nordisk
NVO
$251B
| $5.46M | 1.65% | +60,000 | New | +$5.46M |
|
22
Veracyte
VCYT
$2.39B
| $5.35M | 1.62% | 239,571 +10,120 | +4% | +$226K |
|
23
Gossamer Bio
GOSS
$562M
| $5.11M | 1.55% | +6,130,268 | New | +$5.11M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $5.04M | 1.53% | 407,801 +17,335 | +4% | +$214K |
|
25
Humana
HUM
$36.5B
| $4.87M | 1.48% | +10,000 | New | +$4.87M |
|